Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phase I study of E7010

K Yamamoto1, K Noda, A Yoshimura

  • 1Kinki University School of Medicine, Osaka-Sayama, Osaka, Japan.

Cancer Chemotherapy and Pharmacology
|July 8, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gut microbiome-driven modulation of the tumor immune microenvironment optimizes dual checkpoint blockade in advanced non-small-cell lung cancer.

ESMO open·2026
Same author

Prolonged progression-free survival on epidermal growth factor receptor-tyrosine kinase inhibitors predicts superior response to atezolizumab-based therapy over chemotherapy in epidermal growth factor receptor-mutated non-small-cell lung cancer following progression.

ESMO real world data and digital oncology·2026
Same author

Impact of the Lung Immune Prognostic Index in non-small-cell lung cancer patients with PD-L1-low/negative tumors receiving chemoimmunotherapy: a real-world multicenter retrospective study.

ESMO open·2025
Same author

Effectiveness of post-trastuzumab deruxtecan treatments and incidence of interstitial lung disease in HER2-positive metastatic breast cancer: a real-world, observational cohort study.

ESMO open·2025
Same author

Functional analysis of thermo-sensitive TRPV1 in an aquatic vertebrate, masu salmon (<i>Oncorhynchus masou ishikawae</i>).

Biochemistry and biophysics reports·2022
Same author

Cholesterol 25-hydroxylase is a metabolic switch to constrain T cell-mediated inflammation in the skin.

Science immunology·2021
Same journal

Composition and structure of stratum corneum intercellular lipids in patients with osimertinib-induced hand-foot syndrome.

Cancer chemotherapy and pharmacology·2026
Same journal

CDK4/6 inhibitor-statin interaction and rhabdomyolysis in breast cancer treatment: a case-based systematic review.

Cancer chemotherapy and pharmacology·2026
Same journal

ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.

Cancer chemotherapy and pharmacology·2026
Same journal

Central nervous system penetration of imatinib in acute lymphoblastic leukemia: Pharmacokinetic analysis and clinical implications.

Cancer chemotherapy and pharmacology·2026
Same journal

Severe Methotrexate toxicity after ectopic pregnancy: a case report managed with continuous renal replacement therapy.

Cancer chemotherapy and pharmacology·2026
Same journal

Model-based meta-analysis of individual patient data for the characterization of intravenous 5-fluorouracil population pharmacokinetics.

Cancer chemotherapy and pharmacology·2026
See all related articles

E7010, a novel sulfonamide, shows broad antitumor activity by inhibiting tubulin polymerization and arresting cell cycle progression. Phase I studies established maximum allowable doses and identified peripheral neuropathy as a dose-limiting toxicity, with recommended Phase II doses of 320 mg/m2 (single) and 200 mg/m2/day (5-day).

Area of Science:

  • Oncology
  • Pharmacology
  • Cell Biology

Background:

  • E7010 is a novel sulfonamide with broad-spectrum antitumor activity.
  • Its mechanism involves inhibiting tubulin polymerization, arresting cells in M phase.
  • Discovered using colon 38 carcinoma cells, it targets human tumor xenografts.

Purpose of the Study:

  • Determine the maximum allowable dose (MAD) of E7010.
  • Assess toxicity and pharmacokinetics of single and 5-day repeated doses.
  • Establish recommended Phase II dosing for E7010.

Main Methods:

  • Phase I clinical trial with oral administration of E7010.
  • Single-dose study (16 patients, 80-480 mg/m2) and 5-day repeated-dose study (41 patients, 30-240 mg/m2/day).
  • Evaluation of dose-limiting toxicities, pharmacokinetics (plasma levels, t1/2, AUC), and tumor marker changes.

Related Experiment Videos

Main Results:

  • Dose-limiting toxicities: peripheral neuropathy (single dose), peripheral neuropathy and intestinal paralysis (5-day repeated dose).
  • Favorable pharmacokinetic profile: rapid absorption, elimination (t1/2 4.4-16.6 h), no significant accumulation.
  • Observed tumor response: 74% reduction in spinal cord metastasis, minor response in pulmonary adenocarcinoma, decreased tumor markers (CEA, SCC).

Conclusions:

  • Recommended Phase II doses: 320 mg/m2 (single) and 200 mg/m2/day (5-day repeated).
  • E7010 exhibits time-dependent activity, suggesting divided dosing for sustained blood levels.
  • Further Phase I/II studies recommended with a divided dose schedule for optimal efficacy.